Open Access

Hospitalized patients with HIV and COVID‑19 receiving convalescent plasma: A case series

  • Authors:
    • Richard J. Silvera
    • Hung-Mo Lin
    • Farah Rahman
    • Varun Arvind
    • Helena L. Chang
    • Ian Baine
    • Suzanne A. Arinsburg
    • Nicole M. Bouvier
    • Judith A. Aberg
    • Sean T.H. Liu
  • View Affiliations

  • Published online on: April 26, 2022     https://doi.org/10.3892/wasj.2022.160
  • Article Number: 25
  • Copyright: © Silvera et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of convalescent plasma in coronavirus disease 2019 (COVID‑19) in the general population has not been shown to have a clear benefit. However, there are limited data available on its use in specific populations, such as in persons with human immunodeficiency virus (HIV; PWH). The present case series study describes 12 hospitalized PWH who received convalescent plasma for severe COVID‑19 between March 2020 and July 2020. Demographics, pre‑existing comorbidities, HIV status, and COVID‑19 management were reported and examined in a multivariate analysis. A high mortality rate of 58%, (7 out of 12 PWH) was observed in those receiving the convalescent plasma. By contrast, a brief review of 13 previously published cohorts of PWH hospitalized with COVID‑19 revealed a cumulative mortality of 19% (85 of 439 PWH). In the present case series study, PWH had a significantly higher relative risk for in‑hospital COVID‑19‑associated mortality compared with individuals without HIV (unadjusted range, 2.10‑2.52; and adjusted range, 1.79‑2.08; P<0.02 in all analyses). Covariate‑adjustments were made for patient demographics, pre‑existing co‑morbidities, and mechanical ventilation needs. The high mortality rate of the present case series may be related to random sampling or an adverse effect of convalescent plasma in PWH and severe COVID‑19. Additional research is thus required to investigate the risks and benefits of the use of COVID‑19 convalescent plasma in PWH.

Related Articles

Journal Cover

July-August 2022
Volume 4 Issue 4

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Silvera RJ, Lin H, Rahman F, Arvind V, Chang HL, Baine I, Arinsburg SA, Bouvier NM, Aberg JA, Liu ST, Liu ST, et al: Hospitalized patients with HIV and COVID‑19 receiving convalescent plasma: A case series. World Acad Sci J 4: 25, 2022
APA
Silvera, R.J., Lin, H., Rahman, F., Arvind, V., Chang, H.L., Baine, I. ... Liu, S.T. (2022). Hospitalized patients with HIV and COVID‑19 receiving convalescent plasma: A case series. World Academy of Sciences Journal, 4, 25. https://doi.org/10.3892/wasj.2022.160
MLA
Silvera, R. J., Lin, H., Rahman, F., Arvind, V., Chang, H. L., Baine, I., Arinsburg, S. A., Bouvier, N. M., Aberg, J. A., Liu, S. T."Hospitalized patients with HIV and COVID‑19 receiving convalescent plasma: A case series". World Academy of Sciences Journal 4.4 (2022): 25.
Chicago
Silvera, R. J., Lin, H., Rahman, F., Arvind, V., Chang, H. L., Baine, I., Arinsburg, S. A., Bouvier, N. M., Aberg, J. A., Liu, S. T."Hospitalized patients with HIV and COVID‑19 receiving convalescent plasma: A case series". World Academy of Sciences Journal 4, no. 4 (2022): 25. https://doi.org/10.3892/wasj.2022.160